Toxic Myopathy due to Antidopaminergic Medication Without Neuroleptic Malignant Syndrome.
J Clin Neuromuscul Dis
; 20(2): 94-98, 2018 Dec.
Article
em En
| MEDLINE
| ID: mdl-30439755
Severe recurrent proximal muscle weakness without neuroleptic malignant syndrome secondary to antidopaminergic medication has rarely been reported. We report a 29-year-old man with history of obsessive compulsive disorder and Tourette syndrome who presented with 2 months of worsening dyspnea 3 weeks after starting ziprasidone 40 mg daily that required mechanical ventilation. A year before, after an increased risperidone dose from 0.5 to 1 mg daily, he had developed proximal muscle weakness that spontaneously improved 2 months after discontinuation of risperidone. On this admission, his creatine kinase (CK) was 3318 units/L, and ziprasidone was discontinued. He fully recovered 2 months after discontinuation of ziprasidone, and his CK was 62 units/L. Genetic testing for limb-girdle muscular dystrophy was negative. This case highlights the importance of evaluating CK level in patients taking antidopaminergic medication with any suggestion of muscle weakness to prevent potentially life-threatening complication.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piperazinas
/
Tiazóis
/
Antagonistas de Dopamina
/
Doenças Musculares
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
J Clin Neuromuscul Dis
Assunto da revista:
FISIOLOGIA
/
NEUROLOGIA
Ano de publicação:
2018
Tipo de documento:
Article
País de publicação:
Estados Unidos